On April 29, 2024, Bristol-Myers Squibb (BMS) received priority review approval from the National Medical Products Administration (NMPA) of China for the treatment of adult patients with obstructive hypertrophic cardiomyopathy (HCM) with New York Heart Association (NYHA) cardiac function class I-I for the treatment of improved exercise capacity and symptoms. This is the world's first and currently the only approved cardiac myosin inhibitor.
Hypertrophic cardiomyopathy is a chronic, progressive disease caused by excessive contraction of the myocardium and obstruction of blood filling in the left ventricle, which can lead to debilitating symptoms and cardiac dysfunction, most commonly due to mutations in myocardial sarcomelion proteins.
Mavacamten is a first-in-class myomyosin inhibitor that improves myocardial hypersystolic function in patients with hypertrophic cardiomyopathy by inhibiting calcium-myosin binding and preventing muscle bridge formation. Mavacamten was first developed by MyoKardia and was granted Orphan Drug Designation and Breakthrough Therapy Designation by the FDA. In October 2020, BMS acquired mavacamten for $13 billion in the acquisition of MyoKardia. In April 2022, the product was approved by the FDA for marketing.
Disclaimer: The content is sourced from the Internet, is for informational purposes only, and cannot be used as the sole factor in decision-making.